drugset / Trial / NCT04227327
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
NaSingle-groupOpen-labelTreatment
Summary
The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.
Timeline
- Start
- 2020-01-07
- Primary completion
- 2024-07-25
- Completion
- 2024-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Anastrozole | Other / unclassified | 1 mg | — |
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |